Latest VCEL news and sentiment

Vericel Corporation announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. A webcast of the presentation will be accessible on the investor relations section of the company's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering products like MACI, Epicel, and licensed NexoBrid.

Published

8 Sep 2026 13:52

Catalyst

Market update

Coverage

Direct company

Duplicates

2 consolidated

Vericel Corporation BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe bu

Published

8 Sep 2026 13:30

Catalyst

Market update

Coverage

Direct company

Duplicates

2 consolidated

Vericel Corporation (NASDAQ: VCEL) announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. The company, a leader in advanced therapies for sports medicine and severe burn care, will webcast its presentation via its Investor Relations website. Vericel experienced a moderate negative market reaction with a 2.76% decline in its stock price on September 8, 2026, the day of the announcement.

Published

7 Sep 2026 16:56

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Bank of America Corp DE significantly increased its stake in Vericel Corporation (NASDAQ:VCEL) during the first quarter, purchasing an additional 180,761 shares to own a total of 1.10 million shares valued at $35.3 million. This investment follows a strong financial performance by Vericel, which reported quarterly revenue of $77.46 million, a 22.5% year-over-year increase, and an EPS of $0.04, surpassing analyst expectations. Despite insider selling of 52,232 shares worth approximately $2.3 million in the past three months, analysts maintain a "Moderate Buy" rating for VCEL, with an average price target of $58.40.

Published

15 Aug 2026 09:40

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp (NASDAQ:VCEL) Director Kevin F. McLaughlin exercised stock options for 7,000 shares at $13.05 per share and subsequently sold those shares at $44.53 per share on August 12, 2026. These transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted in May 2025. Following the sale, McLaughlin directly holds 18,300 shares of common stock and 7,000 stock options.

Published

15 Aug 2026 03:43

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp director Kevin F. McLaughlin exercised 7,000 stock options at $13.05 per share and subsequently sold 7,000 common shares at $44.53 per share on August 12, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted in May 2025. The options originated from a 2018 grant for 17,500 shares that vested monthly.

Published

14 Aug 2026 20:43

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Soleus Capital Master Fund, L.P. and associated entities have reported a beneficial ownership of 2.8% in Vericel Corp (VCEL) common stock, totaling 1,458,882 shares. This updated disclosure, filed on an amended Schedule 13G, places their ownership below the 5% threshold, indicating passive investment. All voting and dispositive authority over these shares is shared among the reporting persons.

Published

13 Aug 2026 13:39

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Kevin McLaughlin, an insider at Vericel Corp (VCEL), has filed a notice of proposed sale for 7,000 shares of common stock. This sale is scheduled for on or after August 12, 2026, and is associated with a stock option exercise. McLaughlin previously sold 7,000 shares on May 13, 2026, for $229,777.45, and the current proposed sale has an aggregate market value of $308,770.00.

Published

12 Aug 2026 15:10

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Kopp Family Office LLC significantly reduced its stake in Vericel Corporation (NASDAQ:VCEL) by 68.7% in the second quarter, selling 112,302 shares and retaining 51,053 shares valued at approximately $2.27 million. Despite this, Vericel reported strong Q2 earnings, exceeding expectations with $0.04 EPS and $77.46 million in revenue, a 22.5% year-over-year increase. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $58.40.

Published

11 Aug 2026 10:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

10 Aug 2026 11:36

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

10 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

This article provides current stock information for Vericel Corp (VCEL), including its latest stock price, market cap, and P/E TTM. It notes that more news and updates for VCEL stock will be available soon. The page serves as a hub for news, analysis, financials, and other investment-related data for Vericel Corp.

Published

7 Aug 2026 22:41

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp's Chief Operating Officer, Michael Halpin, exercised stock options to acquire 10,000 shares at $16.66 per share and simultaneously sold these 10,000 shares at $46.84 per share on August 3, 2026. This transaction, executed under a Rule 10b5-1 trading plan established on December 2, 2025, resulted in an approximate pre-tax spread of $302,000. After the transaction, Halpin still holds 26,250 stock options and 16,394 common shares directly.

Published

5 Aug 2026 20:37

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp (FRA:ATQP) reported record Q3 2025 total revenue of $67.5 million, exceeding guidance, primarily driven by a 25% increase in Macy revenue and strong biopsy growth. The company achieved a GAAP net income over $5 million and an adjusted EBITDA margin of 25%, alongside record operating cash flow of over $22 million. Vericel is also preparing to initiate a phase 3 Macy ankle clinical study, indicating future growth opportunities despite anticipated increased operating expenses and caution regarding 2026 guidance.

Published

4 Aug 2026 23:21

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

This article from Investing.com announces the filing of Form 144 by Vericel Corp on August 3rd. Form 144 is a notice of the intent to sell restricted securities, indicating that insiders or affiliates plan to sell shares. The brief note provides the date of the filing and mentions Vericel Corp's stock symbol VCEL.

Published

3 Aug 2026 19:16

Catalyst

Market update

Coverage

Direct company

Duplicates

2 consolidated

Vericel Corporation insider Michael Halpin has filed to sell 10,000 shares of common stock, valued at $459,800.00, on August 3, 2026, through Fidelity Brokerage Services LLC. These shares are related to a stock option exercise on the same date. Halpin also previously sold 10,000 shares on June 18, 2026, for proceeds of $402,401.05.

Published

3 Aug 2026 18:09

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Published

1 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

1 Aug 2026 02:14

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Jonathan Siegal, Principal Accounting Officer at Vericel Corp (VCEL), exercised stock options for 4,500 shares and subsequently sold all 4,500 shares at $48.90 per share on July 30, 2026. The sales were conducted under a Rule 10b5-1 trading plan adopted on December 10, 2025. This transaction involved exercise prices of $34.90 and $29.82 per share, resulting in approximate gross sale proceeds of $220K and a pre-tax spread of $78K.

Published

31 Jul 2026 21:09

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

LEERINK PARTNERS has increased its target price for VERICEL CORP (VCEL.O) to $59.00, up from the previous target of $46.00. This update reflects a significant change in the analyst's valuation of the company. The information was released by Reuters.

Published

31 Jul 2026 19:39

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Key Points Interested in Vericel Corporation? Here are five stocks we like better. Record Q2 performance: Vericel's revenue rose 22% year over year to $77.5 million, while GAAP net income reached $2.2 million and free cash flow totaled $14.3 million. Growth across franchises: MACI revenue increased 23% to a record $65.5 million, while Burn Care revenue climbed 22% to approximately $12 million, led by Epicel and record NexoBrid sales. Higher outlook and shareholder returns: Vericel raised its 2026 revenue guidance to $330 million–$340 million and authorized its first $200 million share-repurcha

Published

31 Jul 2026 10:28

Catalyst

Capital return

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corporation (VCEL) reported second-quarter 2026 earnings and revenue that exceeded Wall Street estimates, driven by strong performance in its MACI cartilage repair and burn care businesses. The company raised its full-year 2026 revenue guidance to $330 million-$340 million and announced a $200 million share repurchase program, its first ever. Management highlighted continued momentum, strategic investments, and robust cash generation, positioning Vericel for sustained growth towards its long-term revenue and profitability targets.

Published

30 Jul 2026 18:40

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel (VCEL) insider Jonathan Siegal filed a Form 144 to sell 4,500 shares of common stock, valued at an aggregate of $220,050.00, following a stock option exercise on July 30, 2026. The sale will be executed through Fidelity Brokerage Services LLC. This filing follows several other share sales by Siegal in the preceding three months, totaling over 7,500 shares.

Published

30 Jul 2026 16:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corporation (VCEL) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +200.00%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.12, delivering a surprise of +20%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Vericel, which belongs to t

Published

30 Jul 2026 14:35

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp Ord (NASDAQ: VCEL) reported second-quarter earnings per share of $0.04, exceeding analyst estimates by $0.07. The company's revenue of $77.45 million also surpassed the consensus estimate of $72.7 million. Vericel Corp Ord's stock has shown strong performance, rising over 31% in the last three months and over 33% in the last year, reflecting a "great performance" in its financial health according to InvestingPro.

Published

30 Jul 2026 14:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corp reported strong second-quarter 2026 results, with revenue rising 22.5% to $77.46M and diluted EPS reaching $0.04 compared to a loss in the prior year. The growth was attributed to increased MACI and Epicel volume, MACI Arthro expansion, and the approval of the Burlington manufacturing facility for MACI production. The company is also pursuing clinical and market expansion initiatives, including the MASCOT ankle trial and UK regulatory approval for MACI.

Published

30 Jul 2026 14:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel reported strong second-quarter 2026 results with total net revenue increasing 22% year-over-year to $77.5 million, driven by growth in MACI, Burn Care, and Epicel. The company raised its full-year 2026 revenue guidance to $330–$340 million and announced a $200 million share repurchase program, highlighting a strong financial position with $227 million in cash and investments.

Published

30 Jul 2026 13:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

2 consolidated

Vericel Corp (VCEL) reported strong Q2 2026 earnings, swinging to profitability with an EPS of $0.04 against an estimated loss of $-0.03, and revenue of $77 million, surpassing estimates of $73 million. The company also announced a $200 million share buyback, indicating confidence in sustained growth, and saw significant growth in MACI cartilage repair revenue and free cash flow.

Published

30 Jul 2026 13:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Vericel Corporation Total Revenue Increased 22% to $77.5 Million, with MACI Revenue Growth of 23% Net Income of $2.2 Million and Free Cash Flow of $14.3 Million Full-Year 2026 Revenue Guidance Raised to $330 to $340 Million Board of Directors Authorizes $200 Million Share Repurchase Program Conference Call Today at 8:30am Eastern Time BURLINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second quarter ended June

Published

30 Jul 2026 12:55

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

This article provides a comprehensive stock analysis of Vericel Corp (VCEL) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis includes its stock score, key insights, analyst ratings (mostly "Buy" with a target price of $57.14), and a comparison with peers. The company is a biopharmaceutical firm specializing in advanced therapies for sports medicine and severe burn care markets, marketing products like MACI, Epicel, and NexoBrid.

Published

30 Jul 2026 11:11

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated